Monoclonal Protein on Serum Protein Electrophoresis (M Component)
Monoclonal gammopathy of unknown significance (MGUS)
Low concentration of monoclonal immunoglobulins (LCMI)
Heavy chain disease
Suggested Additional Lab Testing
For multiple myeloma:
In addition to SPEP followed by immunofixation, quantitative serum immunoglobulin should be performed, because the M component must be greater than3 g/dL in the serum.
Bone marrow aspirate may be useful to show that at least 10% of the nucleated blood cells are plasma cells.
Bone marrow biopsy may be useful to show aggregates of plasma cells in focal or diffuse patterns.
CBC often reveals a normochromic normocytic anemia.
Peripheral blood smear often shows RBCs in a stacked or rouleaux formation.
For Waldenstrom macroglobulinemia:
Immunofixation to identify the M component as an IgM immunoglobulin with a quantitative IgM level greater than 3 g/dL
Serum viscosity is usually increased.
Peripheral blood smear often shows RBC aggregates in a rouleaux formation.
For heavy chain disease:
Immunofixation reveals the heavy chain as alpha, gamma, or mu.
Bone marrow examination may be informative.
Quantitative determination of the serum M component to demonstrate that an IgG or IgM monoclonal protein is less than 3.0 g/dL or an IgA monoclonal protein is less than 2.0 g/dL, or that a Bence-Jones protein is less than or equal to 1.0 g in a 24-hour urine specimen
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Next Article in LabMed
Neurology Advisor Articles
- Ajovy Injection Approved for Migraine Prevention in Adults
- Few With Acute Migraine Take Triptans, Many Discontinue the Drug
- Natalizumab Improves Cognitive Function in Multiple Sclerosis
- Significant Variations in Epilepsy Surgical Strategy, Deficit Reporting Exist
- Thrombolysis With Tenecteplase Is as Safe as Alteplase in Stroke Mimics
- 5 Key Findings Presented at 2018 Parkinson Disease Conference
- Parkinson Disease and the Gut: Treatment Potential Abounds
- Managing Comorbid Migraine and Mood Disorders: A Synergistic Approach
- Stroke-Code Patients With Low NIHSS Score, No Acute Imaging Findings Often Misdiagnosed
- Ethical Challenges of Nusinersen: Considerations When Counseling on Treatment
- Noninvasive Ventilation Effective in Amyotrophic Lateral Sclerosis Treatment
- Gender and Multiple Sclerosis: How It Influences Prognosis and Future Treatment
- Drug Prices Increase More Than Expected After Shortages
- Potentially Inappropriate Opioid Prescribing Tied to Overdose
- Loss of Function Variants in LRKK1 and LRKK2 Not Linked to Parkinson Disease